Pectin-Tannic Acid Nano-Complexes Promote the Delivery and Bioactivity of Drugs in Pancreatic Cancer Cells

Pectin-Tannic Acid Nano-Complexes Promote the Delivery and Bioactivity of Drugs in Pancreatic Cancer Cells

Pancreatic cancer (PanCa) is a lethal disease. Conventional chemotherapies for PanCa offer severe systemic toxicities. Thus, the development of a successful nanomedicine-based therapeutic regimen with augmented therapeutic efficacy is highly sought. Naturally occurring pectin and modified pectin-bas...

Full description

Bibliographic Details
Main Authors:	Sumeet S. Chauhan, Advait B. Shetty, Elham Hatami, Pallabita Chowdhury, Murali M. Yallapu
Format:	Article
Language:	English
Published:	MDPI AG 2020-03-01
Series:	Pharmaceutics
Subjects:	pancreatic cancer nanoparticles gemcitabine irinotecan 5-fluorouracil chemotherapy anticancer drugs
Online Access:	https://www.mdpi.com/1999-4923/12/3/285

Similar Items

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer
by: Volker Kunzmann, et al.
Published: (2014-09-01)

Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients
by: Sauer Rolf, et al.
Published: (2011-07-01)

Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines
by: Bogers, J., et al.
Published: (2022)

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience
by: Danielle C. Glassman, et al.
Published: (2018-06-01)

Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?
by: Emilia Sawicka, et al.
Published: (2016-06-01)

Contemporary Management of Localized Resectable Pancreatic Cancer
by: Anuhya Kommalapati, et al.
Published: (2018-01-01)

Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line
by: Dilara Akhoundova Sanoyan, et al.
Published: (2020-02-01)

WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma
by: Sarah J. Hartman, et al.
Published: (2021-03-01)

Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo
by: Chen YH, et al.
Published: (2020-06-01)

Gemcitabine Combination Nano Therapies for Pancreatic Cancer
by: Kamalika Samanta, et al.
Published: (2019-11-01)

Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
by: Ko AH
Published: (2016-03-01)

Evaluation of response, tolerability and toxicity of new chemotherapeutic regimen in advanced Gastric Cancer
by: Mohammad Ali Mashhadi
Published: (2009-01-01)

Evaluation of response, tolerability and toxicity of new chemotherapeutic regimen in advanced Gastric Cancer
by: Mohammad Ali Mashhadi
Published: (2009-03-01)

Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer
by: I. Grivicich, et al.
Published: (2001-09-01)

Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors
by: Kentaro Minami, et al.
Published: (2015-03-01)

Clinical Value of Pharmacogenomic Testing in a Patient Receiving FOLFIRINOX for Pancreatic Adenocarcinoma
by: Lisa M. Velez-Velez, et al.
Published: (2018-11-01)

Imexon and Gemcitabine: Mechanisms of Synergy against Human Pancreatic Cancer
by: Roman, Nicholas
Published: (2005)

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
by: Ma Yue, et al.
Published: (2011-03-01)

Gemcitabine-Induced Cardiotoxicity in Patients Receiving Adjuvant Chemotherapy for Pancreatic Cancer: A Case Series
by: Salma Alam, et al.
Published: (2018-04-01)

Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
by: Höhler Thomas, et al.
Published: (2004-07-01)

The Molecular Networks of microRNAs and Their Targets in the Drug Resistance of Colon Carcinoma
by: Francesca Crudele, et al.
Published: (2021-08-01)

Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes
by: Megan L. Hutchcraft, et al.
Published: (2021-09-01)

Evaluation of the Expression Profile of Irinotecan-Induced Diarrhea in Patients with Colorectal Cancer
by: Mashiro Okunaka, et al.
Published: (2021-04-01)

Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma
by: Kenneth H. Yu, et al.
Published: (2018-11-01)

FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer
by: Catalano M, et al.
Published: (2020-10-01)

Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?
by: Hyung Sun Kim, et al.
Published: (2021-02-01)

Epibrassinolide Promotes the Apoptotic Potential of Gemcitabine in Pancreatic Cancer Cells
by: Fadina Kuryayeva, et al.
Published: (2019-12-01)

Clinically Meaningful Responses to Sequential Gemcitabine-Based Chemotherapy Regimens in a Patient with Metastatic Pancreatic Cancer
by: Eiko Klimant, et al.
Published: (2013-01-01)

Chemoresistance in Pancreatic Cancer
by: Siyuan Zeng, et al.
Published: (2019-09-01)

Use of Intraoperative Radiotherapy in Pancreatic Cancer After Neoadjuvant Chemoradiotherapy: First National Application
by: Emin KÖSE, et al.
Published: (2016-12-01)

5-Fluorouracil and irinotecan (SN-38) have limited impact on colon microbial functionality and composition in vitro
by: Eline Vanlancker, et al.
Published: (2017-11-01)

Inhibition of the Receptor for Advanced Glycation End Products Enhances the Cytotoxic Effect of Gemcitabine in Murine Pancreatic Tumors
by: Priyanka Swami, et al.
Published: (2021-04-01)

Membrane Drug Transporters and Chemoresistance in Human Pancreatic Carcinoma
by: Ralf Jesnowski, et al.
Published: (2010-12-01)

Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
by: Kenneth H. Yu, et al.
Published: (2021-07-01)

Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers
by: Anant Ramaswamy, et al.
Published: (2018-01-01)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
by: Jane E. Rogers, et al.
Published: (2020-08-01)

hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
by: Jerome Raffenne, et al.
Published: (2019-11-01)

Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives
by: Woo W, et al.
Published: (2019-02-01)

Pancreatic Cancer Chemoresistance to Gemcitabine
by: Manoj Amrutkar, et al.
Published: (2017-11-01)

Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives—An In Vitro Study
by: Marcin Michalak, et al.
Published: (2020-01-01)

Cannot write session to /tmp/vufind_sessions/sess_ean9uvnkqr56rfjlcbd5cqvfvf